EVALUATE THE IMPACT AND CHALLENGES OF ANTIMICROBIAL RESISTANCE IN PNEUMONIA: A CROSS SECTIONAL STUDY IN TERTIARY CARE HOSPITAL
Main Article Content
Keywords
Antimicrobial resistance (AMR), Antibiotic switching, Monotherapy, Pneumonia.
Abstract
Background: The rise of antimicrobial resistance (AMR) poses a significant threat to treating infections like pneumonia. In Pakistan, limited access to culture and sensitivity tests often leads to unchecked infections. Therapy failure and frequent antibiotic switching signal drug resistance and AMR.
Objectives:The study underscores the need for optimized antibiotic use, improved diagnostics, and strategies to combat AMR. Effective solutions will help mitigate resistance, enhance treatment outcomes, and reduce the burden of infections.
MethodologyThe study analyzed 50 pediatric pneumonia cases to assess antibiotic prescription patterns, hospital stay duration, antibiotic consumption, switching, and patient discharge outcomes. This evaluation aimed to understand treatment approaches, identify potential areas for improvement, and optimize patient care.
Results: The study results showed that pneumonia is more common in children (1-5 years); n=20 (40%), followed by neonates (0-12 months); n= 16 (32%), respectively. Monotherapy was used upon initial admission of patients, while combination therapy and antibiotic switching occurred when patients didn't respond. Non-responsiveness prolonged hospital stays, suggesting drug-resistant bacteria.The average hospital stay was 6.5 days with monotherapy and 3.5 days with combination therapy. Cefoperazone (28%), meropenem (26%), and vancomycin/linezolid (20%) were the most prescribed antibiotics. Meropenem+linezolid (n=9) and meropenem+vancomycin (n=7) were common combinations.
Conclusion: The study reveals a concerning trend of drug-resistant bacterial strains causing pneumonia in pediatric patients, signaling a potential silent pandemic of antimicrobial resistance (AMR). This emerging threat requires careful monitoring and reporting to mitigate its consequences.
References
2. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, Davies S: Access to effective antimicrobials: a worldwide challenge. The Lancet 2016, 387:168-175.
3. Fadel SA, Boschi-Pinto C, Yu S, Reynales-Shigematsu LM, Menon GR, Newcombe L, Strong KL, Wang Q, Jha P: Trends in cause-specific mortality among children aged 5–14 years from 2005 to 2016 in India, China, Brazil, and Mexico: an analysis of nationally representative mortality studies. The Lancet 2019, 393:1119-1127.
4. Mackenzie G: The definition and classification of pneumonia. Pneumonia 2016, 8:1-5.
5. Troeger CE, Khalil IA, Blacker BF, Biehl MH, Albertson SB, Zimsen SR, Rao PC, Abate D, Admasie A, Ahmadi A: Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. The Lancet infectious diseases 2020, 20:60-79.
6. Hung IF-N, Tantawichien T, Tsai YH, Patil S, Zotomayor R: Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. International Journal of Infectious Diseases 2013, 17:e364-e373.
7. Ahmed S, Ariff S, Muhammed S, Rizvi A, Ahmed I, Soofi SB, Bhutta ZA: Community case management of fast-breathing pneumonia with 3 days oral amoxicillin vs 5 days cotrimoxazole in children 2-59 months of age in rural Pakistan: A cluster randomized trial. Journal of Global Health 2022, 12.
8. Rothman KJ: Epidemiology: an introduction. Oxford university press; 2022, 10:56.
9. Morrison L, Zembower TRJGEC: Antimicrobial resistance. 2020, 30:619-635.
10. Hayat K, Jamshed S, Rosenthal M, Haq NU, Chang J, Rasool MF, Malik UR, Rehman AU, Khan KM, Fang YJA: Understanding of Pharmacy Students towards Antibiotic Use, Antibiotic Resistance and Antibiotic Stewardship Programs: A Cross-Sectional Study from Punjab, Pakistan. 2021, 10:66.
11. Chokshi A, Sifri Z, Cennimo D, Horng HJJogid: Global contributors to antibiotic resistance. 2019, 11:36.
12. Chua AQ, Verma M, Hsu LY, Legido-Quigley HJTLRH-WP: An analysis of national action plans on antimicrobial resistance in Southeast Asia using a governance framework approach. 2021, 7:100084.
13. Laxminarayan R, Van Boeckel T, Frost I, Kariuki S, Khan EA, Limmathurotsakul D, Larsson DJ, Levy-Hara G, Mendelson M, Outterson KJTLID: The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. 2020, 20:e51-e60.
14. Shanbhag TV, Shenoy S, Nayak V: Pharmacology for Dentistry E-Book. Elsevier Health Sciences; 2021.
15. Sulis G, Sayood S, Gandra S: How can we tackle the overuse of antibiotics in low-and middle- income countries? Expert Review of Anti-infective Therapy 2023.
16. Nimer NA: Nosocomial infection and antibiotic-resistant threat in the Middle East. Infection and drug resistance 2022:631-639.
17. Tattevin P, Levy Hara G, Toumi A, Enani M, Coombs G, Voss A, Wertheim H, Poda A, Daoud Z, Laxminarayan R: Advocacy for increased international efforts for antimicrobial stewardship actions in low-and middle-Income countries on behalf of alliance for the Prudent Use of Antimicrobials (APUA), under the auspices of the International Society of Antimicrobial Chemotherapy (ISAC). Frontiers in Medicine 2020, 7:503.
18. Fostira E, Bitsori M, Vergadi E, Maraki S, Galanakis E: Short‐term antibiotic exposure affected the type and resistance of uropathogens similar to long‐term antibiotic prophylaxis in children hospitalised for urinary tract infections. Acta Paediatrica 2020, 109:1260-1266.
19. Sharma A, Singh A, Dar MA, Kaur RJ, Charan J, Iskandar K, Haque M, Murti K, Ravichandiran V, Dhingra S: Menace of antimicrobial resistance in LMICs: Current surveillance practices and control measures to tackle hostility. Journal of Infection and Public Health 2022, 15:172- 181.
20. Mir F, Ariff S, Bhura M, Chanar S, Nathwani AA, Jawwad M, Hussain A, Rizvi A, Umer M, Memon Z: Risk factors for acute respiratory infections in children between 0 and 23 months of age in a peri-urban district in Pakistan: A matched case–control study. Frontiers in pediatrics 2022, 9:704545.
21. Lee JS, Giesler DL, Gellad WF, Fine MJ: Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. Jama 2016, 315:593-602.
22. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, De Waele J, Daikos GL, Akova M, Harbarth S: European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection 2022, 28:521-547.
23. Khatavkar P, Gulrukh W, Dawane JS, Shreyas D, Pandit V: Understanding about antibiotics and its usage in the community-A pilot study. Health 2021, 40:80.
24. Sano M, Shindo Y, Takahashi K, Okumura J, Sakakibara T, Murakami Y, Iguchi M, Yagi T, Matsui S, Hasegawa Y: Risk factors for antibiotic resistance in hospital-acquired and ventilator-associated pneumonia. Journal of Infection and Chemotherapy 2022, 28:745-752.
25. Al-Madboly LA: A Novel Triple Combination to Combat Serious Infections with Carbapenem-Resistant Acinetobacter baumannii in a Mouse Pneumonia Model. Microbiology Spectrum 2022, 10:e02710-02721.
26. Ramadan RA, Bedawy AM, Negm EM, Hassan TH, Ibrahim DA, ElSheikh SM, Amer RM: Carbapenem-resistant Klebsiella pneumoniae among patients with ventilator-associated pneumonia: Evaluation of antibiotic combinations and susceptibility to new antibiotics. Infection and Drug Resistance 2022:3537-3548.
27. Foucrier A, Dessalle T, Tuffet S, Federici L, Dahyot Fizelier C, Barbier F, Pottecher J, Monsel A, Hissem T, Lefrant JY: Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator- associated pneumonia: an ancillary study of the iDIAPASON trial. Critical Care 2023, 27:211.
28. Onorato L, Macera M, Calò F, Cirillo P, Di Caprio G, Coppola N: Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: A meta-analysis. International Journal of Antimicrobial Agents 2022, 59:106512.
29. Jones F, Hu Y, Coates A: The efficacy of using combination therapy against multi-drug and extensively drug-resistant Pseudomonas aeruginosa in clinical settings. Antibiotics 2022, 11:323.
30. Shah H, Bibi U, Kamal Z, Esa M, Naeem M, Ahmad S, Shafique M: Prescribing Pattern of Ampicillin and Cloxacillin: Sensitivity and Responsiveness in Pneumonia: Antibiotic resistance. Proceedings of the Pakistan Academy of Sciences: B Life and Environmental Sciences 2023, 60:65-75.
31. Roh EJ, Lee M-H, Lee JY, Kim H-B, Ahn YM, Kim JK, Kim HY, Jung S-S, Kim M, Kang EK: Analysis of national surveillance of respiratory pathogens for community-acquired pneumonia in children and adolescents. BMC Infectious Diseases 2022, 22:330.
32. Assefa M, Amare A: Biofilm-Associated multi-drug resistance in hospital-acquired infections: a review. Infection and Drug Resistance 2022:5061-5068.
33. Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, Yao G: The economic burden of antibiotic resistance: A systematic review and meta-analysis. Plos one 2023, 18:e0285170.
34. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MA: Antimicrobial resistance: A growing serious threat for global public health. In Healthcare. MDPI; 2023: 1946.
35. Assefa M: Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. Pneumonia 2022, 14:4.
36. LaPlante KL, Dhand A, Wright K, Lauterio M: Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Annals of Medicine 2022, 54:1686-1700.
37. Bassetti S, Tschudin-Sutter S, Egli A, Osthoff M: Optimizing antibiotic therapies to reduce the risk of bacterial resistance. European journal of internal medicine 2022, 99:7-12.
38. Nimer NA: Nosocomial infection and antibiotic-resistant threat in the Middle East. Infection and drug resistance 2022:631-639.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sonia khan
Associate Professor, Dept of Pharmacology, Al-Tibri Medical College, Karachi, Pakistan
Farhana Shams Abbasi
Senior Lecturer , Ziauddin Medical University, Karachi, Pakistan
Sahiba Hakro
Postgraduate trainee, Ziauddin Medical University, Karachi, Pakistan
Muhammad Latif
Consultant and surgeon, orthopedic Department, Karachi, Pakistan
Fajar Baqer
Consultant physician and diabetologist, Sindh govt hospital liaquatabad, Karachi, Pakistan
Partab Puri
Assistant Professor , Community Medicine, Muhammad Medical College, Mirpurkhas, Pakistan 1.
Mehjabeen
Female Medical Officer, Naka Kharari, Health department, Distinct Hubb, Balochistan, Pakistan
Khusboo Asif
Clinical Data Team Lead , Centre of Disease Control and Prevention, Karachi, Pakistan
Syeda Bushra Zaidi
Senior Compliance Executive, Quality assurance dept, Imam Clinic, Karachi, Pakistan
Muhammad Talha
Product Manager, Intra Health Sciences (Pvt) Ltd, Karachi, Pakistan
Misha Fatima
First year ,Pre Medical student ,Karachi, Pakistan